Indian Research Firm Joins Hands With Alabama Institutions to Develop Innovative Therapies

by Gopalan on  November 24, 2009 at 1:03 PM Corporate News
  •   Print
  •   Share
  •   Comments
  •  Text 
Jubilant Organosys, India has joined hands with the University of Alabama and Southern Research Institute, to develop affordable therapies for a range of metabolic and infectious diseases. Oncology will also be a core area.

Jubilant Organosys is described as the largest Indian research and manufacturing services firm while the Alabama varsity ranks in the top 25 nationally in National Institutes of Health (NIH) funding; it is a rich source of biological targets for drug development. The Southern Research discovered and helped move seven FDA-approved cancer drugs to market, with five more drugs in late-stage preclinical and early clinical studies.

The joint venture will be a U.S.-India arbitraged and leveraged partnership. A Memorandum of Understanding was signed Monday in Washington, DC. Key components of the agreement include:

 --  Selecting the most promising biological targets discovered by

     biomedical researchers at UAB, Southern Research and Jubilant;

 --  Developing new drugs around these targets through work performed at

     UAB and Southern Research, and Jubilant in India;

 --  Using early research data to secure federal funding to create new

     research jobs;

 --  Developing drugs through Preclinical and or Phase 2 clinical trials to

     maximize value to potential licensees, and securing partnerships with

     the pharmaceutical industry; and,

 --  Licensing drugs to the pharmaceutical industry with revenues

     distributed to investment participants in milestone payments and

     royalty streams.

Commenting on the development Shyam S. Bhartia, Chairman and Managing Director, and Hari S Bhartia, Co-chairman and Managing Director, Jubilant Organosys, said, "This novel academic and industrial collaboration demonstrates our commitment to partner with globally renowned academia in order to identify and deliver affordable innovation and healthcare solutions to the patients worldwide. We are happy to join hands with UAB and Southern Research Institute, known for its strengths in the areas of oncology, metabolic disease and infectious diseases. The collective innovation capabilities of this partnership further augments our mission to be the most innovative Drug Discovery and Development group in India, accelerating global drug development."

Page 1 Page 1 | 2  Next
 Email Email   RSS Feeds RSS Feeds   Print this page Print   Save this page Save   Link Link   Syndicate Syndicate   Comments Comments   Bookmark and Share
 
Comment & Contribute
Comments should be on the topic and should not be abusive. Comments are normally moderated and are reviewed after they are posted.
* Your comment can be maximum of 2500 characters

Notify me when reply is posted
I agree to the terms and conditions
  
If you have a question about health related issues, you can now post it in our Ask An Expert section on our community website Medwonders.com and get answers from our panel of experts.
X

Medwonders Health Network

  • Health News Index
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
News Archive
Date :
Category :
Keyword :
  • News Quick Links
News Central Health Watch
Latest Health News Health In Focus
News Category (500+) Breaking Health News
Popular News Celebrating Life
Health News and Press Release Medindia - Exclusive
News Photo Gallery India Special
News Video Gallery Lifestyle and Wellness
News From Other Resources
News Categories:  
Obesity Health Center

Corporate Related News

» Sun Pharma’s ANDA for Azelastine Nasal Spray Gets FDA Nod » Mylan’s ANDA for Clopidogrel Tablets Gets FDA Approval
» Drug Marketing: Abbott Labs Fined $1.6 Billion » The Cancer Cell Line Encyclopedia Launched by Novartis
» LeGoo Maker Pluromed to be Acquired by Sanofi » NGOs Protest Against Novartis' Glivec Lawsuit in India
» Allscripts Expanding India Operations » Bio-Tech Medicine Proves to be Attractive for TCG Lifesciences
Read More >>